UnknownNot Applicable

Combined Therapy for Acne Scars

20 participantsStarted 2021-11-08

Plain-language summary

Compare the effectiveness of nonablative fractional resurfacing to radiofrequency micrnoeedling for facial acne scars in all skin types

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Male or female in general good health ages 18 and older
✓. Fitzpatrick skin type I-VI
✓. Subject has completed an appropriately administered informed consent process which includes signing the IRB approved consent form
✓. Negative urine pregnancy test at baseline (if applicable)
✓. Willingness to have facial exams and digital photos performed of the face
✓. Moderate to severe atrophic acne scarring on the face per ECCA (échelle d'évaluation clinique des cicatrices d'acné) acne grading scale
✓. No change in estrogen releasing contraceptive method in 3 months, and no plans to change this contraceptive method during the course of the study
✓. No change in topical skin care

✕. Presence of incompletely healed wound in treatment area
✕. Pregnant, planning pregnancy or breastfeeding during the course of the study
✕. Energy-based device treatment in the treatment area in the last 6 months
✕. Treatments with a dermal filler or biostimulatory agent in the treatment area within the past 12 months
✕. Recent use of topical tretinoin, adapalene, tazarotene, hydroquinone, imiquimod, 5-fluorouracil, ingenol mebutate, concentrated hydrogen peroxide or diclofenac to the face within the previous 2 weeks.
✕. Individuals who have had a chemical peel or microdermabrasion of the face within 30 days prior to enrollment in the study
✕. Co-existing potentially confounding skin condition within treatment area (e.g. eczema, psoriasis, XP, rosacea) or the presence of suspected BCC or SCC in treatment area at investigator's discretion
✕. Has skin with open wounds, excessively sensitive skin, neurotic excoriations, dermatitis or inflammatory rosacea in the treatment area

Change in atrophic acne scar

Timeframe: 3 months after final treatment

NCT IDNCT05105334

SponsorGoldman, Butterwick, Fitzpatrick and Groff

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-05-08

Sherif Mikhail, MD

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Male or female in general good health ages 18 and older
✓. Fitzpatrick skin type I-VI
✓. Subject has completed an appropriately administered informed consent process which includes signing the IRB approved consent form
✓. Negative urine pregnancy test at baseline (if applicable)
✓. Willingness to have facial exams and digital photos performed of the face
✓. Moderate to severe atrophic acne scarring on the face per ECCA (échelle d'évaluation clinique des cicatrices d'acné) acne grading scale
✓. No change in estrogen releasing contraceptive method in 3 months, and no plans to change this contraceptive method during the course of the study
✓. No change in topical skin care

✕. Presence of incompletely healed wound in treatment area
✕. Pregnant, planning pregnancy or breastfeeding during the course of the study
✕. Energy-based device treatment in the treatment area in the last 6 months
✕. Treatments with a dermal filler or biostimulatory agent in the treatment area within the past 12 months
✕. Recent use of topical tretinoin, adapalene, tazarotene, hydroquinone, imiquimod, 5-fluorouracil, ingenol mebutate, concentrated hydrogen peroxide or diclofenac to the face within the previous 2 weeks.
✕. Individuals who have had a chemical peel or microdermabrasion of the face within 30 days prior to enrollment in the study
✕. Co-existing potentially confounding skin condition within treatment area (e.g. eczema, psoriasis, XP, rosacea) or the presence of suspected BCC or SCC in treatment area at investigator's discretion
✕. Has skin with open wounds, excessively sensitive skin, neurotic excoriations, dermatitis or inflammatory rosacea in the treatment area